Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Businesswire News Releases

May 13, 2024 07:02 ET
POSaBIT Announces Rescheduled FY 2023 Earnings Call
POSaBIT Systems Corporation (CSE: PBIT, OTC: POSAF) (the “Company ” or “ POSaBIT ”), a leading provider of payments infrastructure in the cannabis industry, will report fourth quarter and full year ended December 31, 2023 financial results on May 14, 2024 before the market open. The Company will host a conference call and live webcast at 4:30 PM ET....
May 13, 2024 07:00 ET
Ajax Therapeutics Announces FDA Clearance of IND Application for AJ1-11095, a First-in-Class Type II JAK2 inhibitor, for the Treatment of Myelofibrosis
Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced that it has received clearance for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1clinical study o...
May 13, 2024 07:00 ET
Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic
Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced the closing of an oversubscribed $95 million Series C financing. Proceeds from the financing will be used to support the clinical development of Ajax’s first-in-class T...
May 13, 2024 07:00 ET
Bowhead Specialty Announces Launch of Initial Public Offering
Bowhead Specialty Holdings Inc. (the “Company”, “Bowhead Specialty”, “we” or “our”) announced today the launch of its initial public offering of 6,666,667 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”). The initial public offering price is expected to be between $14.00 and $16.00 per share. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of its common stock at the initial offering price, less underwriting discounts and commissions. The Compan...
May 13, 2024 07:00 ET
D-Wave and the University of Southern California Renew Multiyear Agreement to Advance Annealing Quantum Computing Research and Adoption
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, and the University of Southern California (USC) today announced a renewed multiyear partnership. Under the agreement, the USC Viterbi School of Engineering will...
May 13, 2024 07:00 ET
D-Wave Reports First Quarter 2024 Results
D-Wave Quantum Inc., (NYSE: QBTS) (“D-Wave” or the “Company”) a leader in commercial quantum computing systems, software, and services, today announced financial results for its first fiscal quarter ended March 31, 2024....
May 13, 2024 07:00 ET
GemaTEG™ Introduces DaTEG 1.0: A Revolutionary Thermal Management Solution for AI Servers
GemaTEG™ introduces DaTEG 1.0, a thermal management solution that significantly reduces energy costs and enhances chip performance in AI infrastructures....
May 13, 2024 07:00 ET
Get in on the Bonus Action at Juicy Stakes Casino
Want to receive big bonus cash on some of the most popular diamond and gem-themed slots? Then head to Juicy Stakes Casino right now......
May 13, 2024 07:00 ET
GRAIL to Host Capital Markets Day
GRAIL, LLC., a healthcare company whose mission is to detect cancer early when it can be cured, today will host a virtual Capital Markets Day. Members from GRAIL’s management team will outline growth drivers for Galleri®, a clinically validated, commercially available multi-cancer early detection test, as well as the Company’s scientific expertise, addressable market opportunity, business strategy, and financial profile. GRAIL’s presenters will include Bob Ragusa, Chief Executive Officer, Aaron Freidin, Chief Financial Officer, Joshua Ofman MD, MSHS, President, and Sir Harpal Kumar,...
May 13, 2024 07:00 ET
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow’s rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow’s commitment to enhancing its leadership structure to support the Company’s continued growth. John Saharek, Harrow’s Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow’s commercial business,...
May 13, 2024 07:00 ET
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
Incyte Corporation (Nasdaq:INCY) (the “Company”) today announced that its Board of Directors approved a share repurchase authorization of $2.0 billion. The Company has commenced a modified “Dutch Auction” tender offer to repurchase shares of its common stock for an aggregate purchase price of up to $1.672 billion (the “tender offer”)....
May 13, 2024 07:00 ET
Insight Enterprises, Inc. Announces Investor Meetings for Potential Offering of Senior Notes
Insight Enterprises, Inc. (Nasdaq: NSIT) (the “Company”) announced today that it intends to hold one or more meetings with potential investors with respect to a potential offering of senior notes (the “notes”) in a transaction exempt from the registration requirements under the Securities Act of 1933 (the "Offering"), the proceeds of which are expected to be used to repay a portion of the outstanding borrowings under its senior secured revolving credit facility due 2027 and, to the extent of any remaining net proceeds, for general corporate purposes. There can be no assurance that the C...
May 13, 2024 07:00 ET
Leading Independent Proxy Advisory Firm ISS Recommends Xperi Stockholders Vote “FOR” All Company Nominees on the BLUE Proxy Card
Xperi Inc. (NYSE: XPER) (the “Company” or “Xperi”) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Xperi stockholders vote “FOR” all of the Company’s nominees on the BLUE proxy card ahead of the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”), to be held on May 24, 2024....
May 13, 2024 07:00 ET
Montrose Environmental Group to Present With 3M at the Bank of America Securities 31st Annual Transportation, Airlines, and Industrials Conference
Montrose Environmental Group, Inc. (the “Company,” “Montrose” or “MEG”) (NYSE: MEG) today announced that the Company will present at the Bank of America Securities 31st Annual Transportation, Airlines, and Industrials Conference in New York, NY on Wednesday, May 15, 2024 at 11:50 a.m. Eastern Time....
May 13, 2024 07:00 ET
Moving iMage Technologies Third Quarter Fiscal 2024 Results Conference Call and Webcast
Moving iMage Technologies (NYSE American: MITQ) will host a conference call discussing financial and operational results for its third quarter fiscal 2024 ended March 31, 2024, on Wednesday, May 15, 2024 at 11:00 a.m. Eastern Time....
May 13, 2024 07:00 ET
Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), presents additional results from the international, randomized, double-blind, placebo-controlled study 008A that evaluated the efficacy and safety of evenamide (30 mg bid) as add-on treatment in 291 patients not benefitting from their second-generation antipsychotic medication, including clozapine. Initial top line data announced on 30th April 2024 demonstrated that t...
May 13, 2024 07:00 ET
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update....
May 13, 2024 07:00 ET
ProPetro Appoints Alex Volkov to Board of Directors
ProPetro Holding Corp. (“ProPetro” or the “Company”) (NYSE: PUMP) today announced that, effective May 8, 2024, Alex Volkov has been appointed to its Board of Directors (the “Board”) as ExxonMobil's designee pursuant to the Investor Rights Agreement (the “Investor Rights Agreement”), dated as of December 31, 2018, by and between the Company and Pioneer Natural Resources Pumping Services LLC, a Delaware limited liability company (“Pioneer”), and a wholly owned subsidiary of Exxon Mobil Corporation (“ExxonMobil”)....
May 13, 2024 07:00 ET
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on the company’s development pipeline and reported financial results for the first quarter ended March 31, 2024....
May 13, 2024 07:00 ET
Riveron Deepens Business Advisory Presence in South Florida
Riveron, a national business advisory firm focused on serving the office of the CFO, pri...